Short-term treatment of mild to moderate acute pain. Symptomatic relief of pain and inflammation in osteoarthritis. Symptomatic relief of pain and inflammation in rheumatoid arthritis.
active substance: lornoxicam;
1 tablet contains 8 mg of lornoxicam;
Excipients: lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, Oradry white 03F58750 *.
* Oradry white 03F58750: talc, polyethylene glycol, hydroxypropylmethylcellulose, titanium dioxide (E 171).
Larfix Dosage form
Main physical and chemical properties: oval, oblong, white to yellowish tablets, coated, embossed with “L8” on one side and smooth on the other side.
Larfix Pharmacotherapeutic group
Non-steroidal anti-inflammatory and anti-rheumatic drugs.
ATX code M01A C05.
Larfix Pharmacological properties
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory properties and belongs to the class of oxicams.
Mechanism of action. Lornoxicam inhibits the synthesis of prostaglandins (inhibition of the enzyme cyclooxygenase), which leads to desensitization of peripheral nociceptors and inhibition of inflammation. Lornoxicam also has a central non-anti-inflammatory effect on nociceptors. Lornoxicam does not affect vital signs (eg body temperature, respiratory rate, heart rate, blood pressure, ECG, spirometry).
Absorption. Lornoxicam is rapidly and almost completely absorbed from the gastrointestinal tract. The maximum concentration in blood plasma (Cmax) is reached in 1-2 hours after drug administration. The absolute bioavailability of lornoxicam is 90-100%. The effect of the first passage was not observed. The average half-life is 3-4 hours.
Hypersensitivity to lornoxicam or to components of the drug.
Hypersensitivity (symptoms similar to those of asthma, rhinitis, angioneurotic edema or urticaria) to other NSAIDs, including acetylsalicylic acid.
Severe heart failure.
Gastrointestinal bleeding, cerebrovascular bleeding or other coagulation disorders.
History of gastrointestinal bleeding or perforation of the ulcer associated with previous NSAID therapy.
Acute or recurrent chronic peptic gastric ulcer / history of bleeding (two or more separate proven episodes of ulceration or bleeding).
Severe hepatic insufficiency.
Severe renal insufficiency (serum creatinine> 700 μmol / l).
III trimester of pregnancy (see section “Use during pregnancy or breastfeeding”).
Interaction with other medicinal products and other forms of interaction
The effect of other drugs on lornoxicam.
increased plasma concentrations of lornoxicam (no interaction was found between lornoxicam and ranitidine or lornoxicam and antacids).
Effects of lornoxicam on other drugs.
Anticoagulants: NSAIDs may increase the effect of anticoagulants, such as warfarin (see section 4.4). The international normalized index should be closely monitored.
Phenprocoumon: The effectiveness of phenprocoumon treatment is reduced.
ACE inhibitors: may reduce the effect of ACE inhibitors.